On October 3, 2023 Nob Hill Therapeutics (NHT), a VIC Technology Venture Development portfolio company, reported that it has received an HHS phase II grant (up to $2M) to develop an inhaled therapy to treat lung cancer. The funds will be used to scale-up and optimize the drug powder formulation, to test the formulation with NHT’s first-of-its-kind dry powder nebulizer delivery platform technology, and to conduct other pre-IND studies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NHT will collaborate on the grant activities with Lovelace Biomedical, a not-for-profit preclinical contract research organization.

Noel Greenberger, CEO of NHT, said "This grant certainly presents an exciting opportunity for Nob Hill and Lovelace Biomedical. More importantly, it is the next step in providing a therapy that could help lung cancer patients and physicians battle this particularly devastating form of cancer."

Paul J Atkins, PhD, Executive Chairman NHT, added "This is an exciting time for Nob Hill. We continue to build on NHT’s vision to advance the lung disease treatment paradigm by being the leading provider of high-dose lung delivery solutions."

There are over 2 million lung cancer cases each year globally, and lung cancer is the leading cause of cancer-related deaths in the US and Europe.

NHT has a patent-protected inhalation device technology capable of delivering high therapeutic doses directly to the lung. It is suitable for patients of all ages and inhalation capabilities.